Toward the end of this decade, a choice may face the species that could reshape its interactions with intelligence itself and ...

Former Google CEO Eric Schmidt expressed astonishment at AI's rapid progress, particularly its ability to autonomously generate code, admitting his ow ...

With the popularity of AI coding tools rising among some software developers, their adoption has begun to touch every aspect ...

November's wave of FDA oncology approvals signals the industry's shift toward platform-based precision therapies over broad-spectrum approaches([1]) . The global anticancer drug market now values ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

...leading to cascading recursive implosion! Scoping internals via origin may be a wise move; perhaps a stop_hook_active-esque for prompt-based hooks? Otherwise a depth counter, parentId chaining, etc ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...